Eytan Stein, MD, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations.
Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations. Stein says historically, oncologists have been giving induction chemotherapy and consolidation chemotherapy, which he says is non-specific and does an "okay job" at initially benefitting patients with acute myeloid leukemia before relapse.
Stein cites a recent phase III trial researching the drug midostaurin (PKC412), which inhibits FLK3, in combination with chemotherapy versus chemotherapy alone. He says the overall survival advantage of the combination is about 7% of 5 years, which is proof of principle for oncologists to begin considering the combination in their treatment paradigms.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More